Influence of polymorphisms in CYP2C9 , VKORC1 , MDR1 and APOE genes on the warfarin maintenance dose in Brazilian patients.
Emílio Itamar de Freitas CamposKarina Braga GomesDaniel Dias RibeiroMarja Kaarina PuurunenAline de Oliveira Magalhães MourãoIsadora Gonçalves FerreiraManoel Otávio da Costa RochaRenan Pedra de SouzaMaria Auxiliadora Parreiras MartinsPublished in: Pharmacogenomics (2023)
Background: Polymorphisms in the CYP2C9 , VKORC1 , MDR1 and APOE genes may impact warfarin dose. Aim: To investigate the influence of sociodemographic and clinical factors and polymorphisms *1 , *2 and *3 for CYP2C9 , -1639G>A for VKORC1 , 3435C>T for MDR1 , and ϵ2, ϵ3 and ϵ4 for APOE genes on the mean weekly warfarin maintenance dose in adults. Methods: This cross-sectional study recruited a calculated sample of 315 patients in three anticoagulation clinics in Brazil. A model containing the variables significantly associated with warfarin dose was estimated. Results: The mean age of patients was 64.1 ± 13.1 years, with 173 (54.9%) women. Age, use of amiodarone, genotype VKORC1 GA, genotype VKORC1 AA, genotypes CYP2C9*1/*2 or *1/*3 and genotypes CYP2C9*2/*2 or *2/*3 or *3/*3 were associated with a reduced warfarin dose. Conclusion: This study pointed out factors that could impact the management of oral anticoagulation.
Keyphrases
- end stage renal disease
- atrial fibrillation
- venous thromboembolism
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- multidrug resistant
- direct oral anticoagulants
- cognitive decline
- type diabetes
- gene expression
- genome wide
- pregnant women
- adipose tissue
- insulin resistance
- skeletal muscle
- polycystic ovary syndrome
- pregnancy outcomes